Belgium· BE-AMP-SAM661968-00

Jaypirca 100 mg

A pirtobrutinib product containing pirtobrutinib, registered in Belgium by Eli Lilly Nederland. The same ATC class is registered in 13 of our 19 countries.

ATC L01EL05

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedJaypirca 100 mgATCL01EL05REGISTER NO.BE-AMP-SAM661968-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Pirtobrutinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EL05 (pirtobrutinib), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Pirtobrutinib · ATC L01EL05

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pirtobrutinib costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.20 in France to $369.10 in Switzerland — a ×1801 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Pirtobrutinib · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$369.10
  • FR France$0.20
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Pirtobrutinib
Manufacturer
Eli Lilly Nederland
Country
Belgium (BE)
ATC code
L01EL05
ATC class
Pirtobrutinib
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    4829487
  • be_apb
    7742265

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Pirtobrutinib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pirtobrutinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Jaypirca
  • Liechtenstein · Jaypirca
  • Norway · Jaypirca

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f250c165-a391-46c4-82d1-1eca97eecfd7
GET /v1/drugs/f250c165-a391-46c4-82d1-1eca97eecfd7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Jaypirca 100 mg",
  "name_fr": "Jaypirca 100 mg",
  "name_nl": "Jaypirca 100 mg",
  "amp_code": "SAM661968-00",
  "strengths": [
    "100.0000",
    "100.0000",
    "77.0000"
  ],
  "pack_count": 6,
  "substances": [
    "Pirtobrutinib",
    "Lactose"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Pirtobrutinib",
  "authorisation_numbers": [
    "EU/1/23/1738/008",
    "EU/1/23/1738/005",
    "EU/1/23/1738/009",
    "EU/1/23/1738/007",
    "EU/1/23/1738/004",
    "EU/1/23/1738/006"
  ]
}

See everything about pirtobrutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.